Open AccessNK Cells: Key to Success of DC‐Based Cancer Vaccines?
Author(s) -
Lion Eva,
Smits Evelien L.J.M.,
Berneman Zwi N.,
Van Tendeloo Viggo F.I.
Publication year - 2012
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2011-0122
Subject(s) - medicine , immune system , immunotherapy , cancer immunotherapy , immunology , vaccination , cytotoxic t cell , dendritic cell , acquired immune system , innate immune system , clinical trial , cancer research , biology , in vitro , biochemistry
Learning Objectives After completing this course, the reader will be able to: Describe the current in vivo experimental and clinical dendritic cell (DC) vaccination studies encompassing the monitoring of natural killer (NK) cells. Discuss the evaluation of NK cell stimulating potency in the design of DC‐based cancer vaccines in the preclinical phase and in clinical trials. Explain the added value of immune monitoring of NK cells in cancer vaccination trials.This article is available for continuing medical education credit at CME.TheOncologist.com The cytotoxic and regulatory antitumor functions of natural killer (NK) cells have become attractive targets for immunotherapy. Manipulation of specific NK cell functions and their reciprocal interactions with dendritic cells (DCs) might hold therapeutic promise. In this review, we focus on the engagement of NK cells in DC‐based cancer vaccination strategies, providing a comprehensive overview of current in vivo experimental and clinical DC vaccination studies encompassing the monitoring of NK cells. From these studies, it is clear that NK cells play a key regulatory role in the generation of DC‐induced antitumor immunity, favoring the concept that targeting both innate and adaptive immune mechanisms may synergistically promote clinical outcome. However, to date, DC vaccination trials are only infrequently accompanied by NK cell monitoring. Here, we discuss different strategies to improve DC vaccine preparations via exploitation of NK cells and provide a summary of relevant NK cell parameters for immune monitoring. We underscore that the design of DC‐based cancer vaccines should include the evaluation of their NK cell stimulating potency both in the preclinical phase and in clinical trials.